VT-1161: Interim Phase IIb data

Interim data from about 100 patients with recurrent vulvovaginal candidiasis in the double-blind, U.S. Phase IIb REVIVE trial showed that 150 and 300 mg oral VT-1161 once daily for 7 days and then onc...